Tiapride
| Evidence Level: L2 | Predicted Indications: 1 |
Table of Contents
Tiapride: Toward a New Indication in Migraine Disorder
One-Sentence Summary
Tiapride’s original approved indication is not documented in the current evidence pack (no India market licenses on record). The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 10 publications (dating from 1978–2022) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no India licenses on record in this evidence pack |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.18% |
| Evidence Level | L2 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on the repurposing rationale provided, Tiapride is a selective dopamine D2/D3 receptor antagonist of the benzamide class, in the same pharmacological family as sulpiride.
Migraine pathophysiology includes the “dopamine hypersensitivity hypothesis,” which links premonitory symptoms (yawning, nausea, mood changes) to central dopaminergic hyperactivity. Other D2 antagonists — notably metoclopramide and prochlorperazine — are already used clinically in acute migraine treatment, lending pharmacological plausibility to this drug class’s applicability in migraine.
This mechanistic reasoning is inferred from known pharmacology of the benzamide class, not from an officially documented indication linkage, since Tiapride’s original MOA record is itself a data gap. The connection should be treated as hypothesis-generating rather than confirmed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35548913 | 2022 | RCT | Revista de Neurología | Randomised, double-blind pilot study comparing tiapride and topiramate for prophylaxis of chronic migraine |
| 6256904 | 1980 | RCT | La Semaine des Hôpitaux | Placebo-controlled study in 40 migraine patients; tiapride showed clear efficacy |
| 6266020 | 1981 | RCT | La Semaine des Hôpitaux | Controlled trial in 25 patients with intractable migraine/facial vascular pain; excellent results in 10 cases, recommended after failure of usual therapy |
| 6293072 | 1982 | Cohort | La Semaine des Hôpitaux | 180 patients treated; good/excellent results in 71% of the 110 completers with cephalalgia of varied causes |
| 7323625 | 1981 | Cohort | Rivista di Patologia Nervosa e Mentale | Double-blind trial, 300 mg/day for 30 days in 50 patients (mixed headache + classic migraine); 65% showed clinical benefit |
| 6528587 | 1984 | Review | Wiadomości Lekarskie | Review of benzamides (sulpiride, tiapride) in preventive treatment of migraine |
| 211624 | 1978 | Review | La Semaine des Hôpitaux | Discusses tiapride’s combined antalgic, antiemetic, and mild anticompulsive action for headache/migraine |
| 35831 | 1978 | Review | La Semaine des Hôpitaux | General review of chronic headache treatment approaches, including psychotropic options |
| 39344 | 1979 | Case Series | La Semaine des Hôpitaux | 4 case observations treated ≥6 months; all showed excellent or very good results |
| 229563 | 1979 | Case Series | La Semaine des Hôpitaux | 47 elderly patients (66–99 yrs) treated with tiapride for various indications including dyskinesia and agitation |
India Market Information
Tiapride is currently not registered or marketed in India (0 licenses on record in this evidence pack).
Safety Considerations
Please refer to the package insert for safety information. Note: local safety label data (warnings, contraindications, and drug-drug interactions) is currently a Blocking-severity data gap (DG001) — this must be resolved before any S1 safety pre-assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: While the pharmacological rationale is plausible and evidence level L2 is supported by several small, mostly older controlled trials (1978–2022) suggesting migraine benefit, the drug is not currently marketed in India and a Blocking-severity data gap prevents safety pre-assessment (S1). The evidence base also predates modern migraine trial standards and lacks large, contemporary RCTs.
To proceed, the following is needed:
- India/local package insert data — key warnings, contraindications, drug-drug interactions (DG001, Blocking)
- Confirmed original indication and MOA documentation (DG002, High)
- Assessment of whether more recent, larger RCTs (beyond the 2022 pilot study) exist or are planned
- India regulatory pathway analysis given current unregistered status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.